A Novel Combination Treatment Targeting BCL-X-L and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Sung-Yup | - |
dc.contributor.author | Han, Jee Yun | - |
dc.contributor.author | Na, Deukchae | - |
dc.contributor.author | Kang, Wonyoung | - |
dc.contributor.author | Lee, Ahra | - |
dc.contributor.author | Kim, Jooyoung | - |
dc.contributor.author | Lee, Jieun | - |
dc.contributor.author | Min, Seoyeon | - |
dc.contributor.author | Kang, Jinjoo | - |
dc.contributor.author | Chae, Jeesoo | - |
dc.contributor.author | Kim, Jong-Il | - |
dc.contributor.author | Park, Hansoo | - |
dc.contributor.author | Lee, Won-Suk | - |
dc.contributor.author | Lee, Charles | - |
dc.date.available | 2020-02-27T16:44:32Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2017-10 | - |
dc.identifier.issn | 1535-7163 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/5620 | - |
dc.description.abstract | Colorectal cancer is the third most commonly diagnosed cancer in the world, and exhibits heterogeneous characteristics in terms of genomic alterations, expression signature, and drug responsiveness. Although there have been considerable efforts to classify this disease based on high-throughput sequencing techniques, targeted treatments for specific subgroups have been limited. KRAS and BRAF mutations are prevalent genetic alterations in colorectal cancers, and patients with mutations in either of these genes have a worse prognosis and are resistant to anti-EGFR treatments. In this study, we have found that a subgroup of colorectal cancers, defined by having either KRAS or BRAF (KRAS/BRAF) mutations and BCL2L1 (encoding BCLXL) amplification, can be effectively targeted by simultaneous inhibition of BCL-XL (with ABT-263) and MCL1 (with YM155). This combination treatment of ABT-263 and YM-155 was shown to have a synergistic effect in vitro as well as in in vivo patient-derived xenograft models. Our data suggest that combined inhibition of BCL-XL and MCL1 provides a promising treatment strategy for this genomically defined colorectal cancer subgroup. (C) 2017 AACR. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | AMER ASSOC CANCER RESEARCH | - |
dc.relation.isPartOf | MOLECULAR CANCER THERAPEUTICS | - |
dc.subject | SYNTHETIC LETHAL INTERACTION | - |
dc.subject | TUMOR-GROWTH | - |
dc.subject | APOPTOSIS RESISTANCE | - |
dc.subject | ANTITUMOR ACTIVITIES | - |
dc.subject | DOWN-REGULATION | - |
dc.subject | RAS MUTATIONS | - |
dc.subject | KRAS | - |
dc.subject | MEK | - |
dc.subject | INHIBITION | - |
dc.subject | CETUXIMAB | - |
dc.title | A Novel Combination Treatment Targeting BCL-X-L and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000412220900012 | - |
dc.identifier.doi | 10.1158/1535-7163.MCT-16-0735 | - |
dc.identifier.bibliographicCitation | MOLECULAR CANCER THERAPEUTICS, v.16, no.10, pp.2178 - 2190 | - |
dc.identifier.scopusid | 2-s2.0-85030645478 | - |
dc.citation.endPage | 2190 | - |
dc.citation.startPage | 2178 | - |
dc.citation.title | MOLECULAR CANCER THERAPEUTICS | - |
dc.citation.volume | 16 | - |
dc.citation.number | 10 | - |
dc.contributor.affiliatedAuthor | Lee, Won-Suk | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | SYNTHETIC LETHAL INTERACTION | - |
dc.subject.keywordPlus | TUMOR-GROWTH | - |
dc.subject.keywordPlus | APOPTOSIS RESISTANCE | - |
dc.subject.keywordPlus | ANTITUMOR ACTIVITIES | - |
dc.subject.keywordPlus | DOWN-REGULATION | - |
dc.subject.keywordPlus | RAS MUTATIONS | - |
dc.subject.keywordPlus | KRAS | - |
dc.subject.keywordPlus | MEK | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordPlus | CETUXIMAB | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.